This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Performance of a New Glucose Meter System in Children and Young Adults

This study has been completed.
Information provided by (Responsible Party):
Ascensia Diabetes Care Identifier:
First received: September 24, 2009
Last updated: January 29, 2016
Last verified: January 2016
The purpose of this study is to evaluate the performance of a new blood glucose meter in the hands of children, teens, young adults.

Condition Intervention
Diabetes Device: DIDGET (Investigational Blood Glucose Monitoring System)

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Performance of the DIDGET Blood Glucose Monitoring System in Children and Young Adults

Resource links provided by NLM:

Further study details as provided by Ascensia Diabetes Care:

Primary Outcome Measures:
  • Percent of Blood Glucose (BG) Results Within +/-15mg/dL or +/-20% of Laboratory Glucose Method [ Time Frame: 1-2 hours ]
    Subjects with diabetes and healthcare professionals (HCPs) used a new blood glucose monitoring system (BGMS) with subject blood. BGM results were compared to a lab glucose method - Yellow Springs Instrument (YSI) Analyzer. Duplicate BG results were used to calculate the number of BG results within +/-15mg/dL (for reference BG results <75mg/dL) or +/- 20% (for reference BG values >/=75mg/dL) of the reference method results.

Enrollment: 123
Study Start Date: September 2009
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Subjects with diabetes
Subjects with diabetes (or parents/guardians, if applicable)and healthcare professionals (HCPs) use a new blood glucose monitoring system. Subjects were 4 to 24 years of age with type 1 and type 2 diabetes.
Device: DIDGET (Investigational Blood Glucose Monitoring System)
Subjects with diabetes (with parent/guardian assistance, if applicable)and health care professionals (HCPs) each performed duplicate Blood Glucose (BG) tests from the subject's capillary blood on the DIDGET. To test the full range of glucose concentrations, a venipuncture was performed on some subjects to obtain enough blood for modifying (spiking or glycolyzing) to the extreme glucose concentrations. Results were compared to a laboratory glucose method - the Yellow Springs Instrument (YSI) Analyzer.


Ages Eligible for Study:   4 Years to 24 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 1 or Type 2 diabetes
  • Age 4 to 24 years
  • Routinely performs blood glucose testing at home
  • If age 18 or older at time informed consent is signed, subject must be able to speak, read, and understand English.
  • If younger than age 18, subject's parent/guardian must be able to speak, read, and understand English, and is able to provide appropriate supervision.
  • Is willing to complete all study procedures, with or without parent / guardian supervision, if appropriate

Exclusion Criteria:

  • Currently pregnant
  • Hemophilia or any other bleeding disorder
  • Taking prescription anticoagulants (such as Warfarin or heparin) or has clotting problems that may prolong bleeding. Taking Plavix or aspirin daily is not excluded
  • Infection with a blood borne pathogen (e.g., HIV, hepatitis)
  • Subject or parent/guardian is employee of competitive medical device company
  • Cognitive disorder or other condition, which in the opinion of the investigator, would put the person at risk or seriously compromise the integrity of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00985257

United States, California
AMCR Institute
Escondido, California, United States, 92026
United States, Florida
Larry C. Deeb, MD PA
Tallahassee, Florida, United States, 32308
Sponsors and Collaborators
Ascensia Diabetes Care
Principal Investigator: Timothy Bailey, MD AMCR Institute
Principal Investigator: Larry C Deeb, MD PA Larry C. Deeb, MD PA
  More Information

Responsible Party: Ascensia Diabetes Care Identifier: NCT00985257     History of Changes
Other Study ID Numbers: CTD-2009-35
Study First Received: September 24, 2009
Results First Received: April 6, 2010
Last Updated: January 29, 2016 processed this record on August 18, 2017